Allergen-specific immunotherapy in childhood asthma

Current Opinion in Pediatrics

Volumn 9, Issue 6, 1997, Pages 582-584

  Eggleston, Peyton A ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLERGEN;

AIRBORNE PARTICLE; ALLERGIC RHINITIS; ANAPHYLAXIS; ANT; ASTHMA; CAT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DERMATOPHAGOIDES PTERONYSSINUS; HUMAN; HYMENOPTERA; IMMUNOTHERAPY; INSECT STING; META ANALYSIS; MOULD; POLLEN; PRIORITY JOURNAL; REMISSION; RHINITIS; SHORT SURVEY; SYMPTOM;

EID: 0031437379     PISSN: 10408703     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008480-199712000-00006     Document Type: Short Survey

References (12)

1. Eggleston, PA: Immunotherapy in allergic respiratory disease. Ped Clin N Am 1988, 35:1103-1113.
2. Valentine MD, Schuberth KC, Kagey-Sobotka A, Graft DF, Kwiterovich KA, Szklo M, Lichtenstein LM: The value of immunotherapy in children with allergy to insect stings. N Engl J Med 1990, 323:1061-1063.
3. Reid MJ, Lockey RF, Turkeltaub PC, Platts-Mills TAE: Survey of fatalities from skin testing and immunotherapy 1985-1989. J Allergy Clin Immunol 1993, 92:6-15.
4. Abramson MJ, Puy RM, Weiner JM: Is allergen immunotherapy effective in asthma: A meta-analysls of randomized controlled trials. Am J Resp Crit Care Med 1995, 151:969-974.
5. Creticos PS, Reed CE, Norman PS, Khoury J, Adkinson NF Jr, Gadde J, Li JT, Richerson HB, Rosenthal RR, Solomon WR, et al.: Ragweed immunotherapy in adult asthma. N Engl J Med 1996, 334:501-506. An important multicenter trial of allergen immunotherapy in highly selected adults with asthma almost exclusively related to seasonal allergen exposure.
6. Adkinson NF Jr, Eggleston PA, Eney D, Goldstein EO, Schuberth KC, Bacon JR, Hamilton RG, Weiss ME, Arshad H, Meinert CL, et al.: A controlled trial of immunotherapy for asthma in allergic children. N Engl J Med 1997, 336:324-331. The first trial with mixtures of multiple allergenic extract. This form of therapy is the customary method used in the United States, but has never been subjected to formal double-blind, placebo-controlled clinical trials.
7. OHehir RE, Garman r, Greenstein J, Lamb JR: The specificity and regulation of T cell responsiveness to allergen. Ann Rev Immunol 1991, 9:67-95.
8. Lack G, Nelson HS, Amran D, Oshiba A, Jung T, Bradley KL, Giclas PC, Gelfand EW: Rush immunotherapy results in allergen-specific alterations in lymphocyte function and interferon-γ production in CD4+ T cells. J Allergy Clin Immunol 1997, 99:530-538.
9. Briner TJ, Kuo M-C, Keating KM, Rogers BL: Peripheral T-cell tolerance induced in naive and primed mice by subcutaneous injection of peptides from the major cat allergen Fel d 1. Proc Nat Acad Sci USA 1993, 90:7608-7612.
10. Simons FER, Imada M, Li Y, Watson WTA, Hayglass KT: Fel d 1 peptides; effect on skin tests and cytokine synthesis in cat-allergic human subjects. Int Immunol 1997, 8:1937-1945. The second report of clinical trials with allergen peptide fragments, describing the immunologic consequences of therapy.
11. Norman PS, Ohman JL Jr, Long AA, Creticos PS, Gefter MS, Shaked Z, Wood RA, Eggleston PA, Hafner KB, Rao P, Lichtenstein LM, Jones NH, Nicodemus CF: Treatment of cat allergy with T cell reactive peptides. Am J Respir and Crit Care Med 1996, 154:1623-1628. The first report of clinical trials in humans with this important new therapy, describing the activity and side effects.
12. Norman PS, Nicodemus CF, Creticos PS, Wood RA, Eggleston PA, Lichtenstein LM, Kagey-Sobotka A, Proud D: Clinical and immunologic effects of component peptides in Allevax Cat. Int Arch Allergy Immunol 1997, 113:224-226. The third report of clinical trials, with further analysis of clinical benefit, as well as immunologic consequences.